Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Select Medical Holdings (SEM) EBIT (2018 - 2025)

Select Medical Holdings (SEM) has disclosed EBIT for 8 consecutive years, with $63.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 128.47% to $63.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $438.7 million, a 302.92% increase, with the full-year FY2025 number at $336.2 million, up 25.29% from a year prior.
  • EBIT was $63.9 million for Q4 2025 at Select Medical Holdings, down from $107.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $284.0 million in Q2 2021 to a low of -$224.6 million in Q4 2024.
  • A 5-year average of $98.0 million and a median of $119.1 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 321.39% in 2022, then skyrocketed 166.56% in 2023.
  • Select Medical Holdings' EBIT stood at $77.5 million in 2021, then tumbled by 321.39% to -$171.7 million in 2022, then surged by 166.56% to $114.3 million in 2023, then plummeted by 296.57% to -$224.6 million in 2024, then skyrocketed by 128.47% to $63.9 million in 2025.
  • Per Business Quant, the three most recent readings for SEM's EBIT are $63.9 million (Q4 2025), $107.4 million (Q3 2025), and $119.8 million (Q2 2025).